The trajectory of Sildenafil presents a complex case for investors in the medicinal sector. While here initially a blockbuster success, generating billions, the intellectual property lapse and the subsequent entry of off-brand competitors have drastically affected earnings. This presents questions about the long-term viability of related drug proje